With a view to improving quality of treatment, the country’s first government recognised diabetes treatment guideline launched on Tuesday.
“Diabetes Care BADAS Guideline 2019” was prepared jointly by Diabetic Association of Bangladesh (BADAS) and Non-Communicable Diseases Control Programme of Directorate General of Health Services.
Additionally, to introduce digital approach in healthcare and empower physicians, an application-based treatment approach, Diabetes Journey was also launched on the same day. The app was launched jointly by BADAS and Novo Nordisk based on the new diabetes treatment guideline. The guideline and application were launched at Dhaka Club.
This guideline will help to model and standardise the treatment outline of the diabetic patients, and will ensure optimal control for better outcome, said Professor Dr. AK Azad Khan, President of BADAS.
The diabetes journey app will empower the physicians to take effective treatment decisions based on patients’ types and needs, Dr. Khan said.
BADAS aims to transform diabetes care in Bangladesh so that patients can have access to quality care and better health, said Md. Sayef Uddin, General Secretary of BADAS.
As a global leader in diabetes care, Novo Nordisk has taken many initiatives to introduce digital approach in healthcare, said Anand Shetty, Managing Director of Novo Nordisk.
The diabetes journey application and the country’s first national diabetes patients’ registry are few examples of digitalisation in Bangladesh and aligned with the government’s vision for “Digital Bangladesh”, Shetty said.
Winnie Estrup Petersen, Ambassador, Embassy of Denmark said that addressing non-communicable diseases is one of the major steps to achieve sustainable development goals in health sector and she is pleased to see the positive steps taken by the Bangladesh government in this regard.
“I am happy to know that Novo Nordisk’s local production facility will provide further access to quality insulin to patients living with diabetes,” said the Ambassador.
Dr. Md. Faruque Pathan, Professor, Department of Endocrinology at BIRDEM General Hospital; Dr. Abdul Alim, Assistant Director, Non-Communicable Diseases Control Programme, Directorate General of Health Services; Dr. Bishwajit Bhowmik, Coordinator, Centre for Global Health Research, BADAS; Dr. Mohammad Mahbubur Rahman, Head of Medical and Quality of Novo Nordisk; and Md. Tanbir Sajib, Head of Commercial Affairs of Novo Nordisk were present.